lutropin alpha
Trade name: luveris
Recombinant proteinapproved
Approved
Aug 22, 1975
Luteinizing hormone is a hormone produced by gonadotropic cells in the anterior pituitary gland. The production of LH is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus. In females, an acute rise of LH known as an LH surge, triggers ovulation and development of the corpus luteum. In males, where LH had also been called interstitial cell–stimulating hormone (ICSH), it stimulates Leydig cell production of testosterone. It acts synergistically with follicle-stimulating hormone (FSH). — Wikipedia
Clinical trial activity
60 trials · 61 clinical orgs · 4 marketing orgs
Phase 1
8
Phase 2
18
Phase 3
11
Phase 4
19
Earliest trial started Dec 1, 1999 (NCT01735422)
Timeline
Indications
Studied for
- Amenorrhea · Phase 4
- Clomiphene · Phase 4
- Endometrial Hyperplasia · Phase 2/Phase 3
- Endometrial Neoplasms · Phase 2/Phase 3
- Fertility · Phase 3
- Fertility Preservation · Phase 3
- Fertilization in Vitro · Phase 4
- Gonadotropin-Releasing Hormone · Phase 4
- Healthy Volunteers · Phase 1
- Hormones · Phase 3
- Hyperprolactinemia · Phase 4
- Hypogonadism · Phase 4
- Infertility · Phase 4
- Infertility, Female · Phase 4
- Ovarian Diseases · Phase 4
- Ovarian Hyperstimulation Syndrome · Phase 4
- Ovarian Reserve · Phase 2
- Ovulation · Phase 4
- Ovulation Induction · Phase 4
- Polycystic Ovary Syndrome · Early Phase 1
- Pregnancy · Phase 4
- Pregnancy Complications · Phase 4
- Progesterone · Phase 4
- Reproductive Techniques, Assisted · Phase 3
- Sleep Disorders, Intrinsic · Phase 1
Mechanism of action
LHCGR agonist
It's LH, used to stimulate development of a potentially competent follicle and to indirectly prepare the reproductive tract for implantation and pregnancy
- Luteinizing hormone/Choriogonadotropin receptorSupplementation
LHCGR supplementation
Combination products
menotropins
with urofollitropin
Approval history
- approvedAug 22, 1975
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaLuteinizing hormone ↗
- NCATS3JGY52XJNA ↗
- ChEMBLCHEMBL1201697 ↗
- ChEMBLCHEMBL1201419 ↗
Also known as
- atc g03 ga gonadotropins
- follitropin alfa /lutropin alfa
- icsh
- insterstiial cell-stimulating hormone
- leuveris
- lh
- lh
- lh-b
- lsh-b
- lsh- beta
- luteinising hormone
- luteinising hormone
- luteinising hormone
- luteinising hormone
- luteinizing hormone
- luteinizing hormone
- luteinizing hormone
- luteinizing hormone beta subunit
- lutrophin
- lutropin
- lutropina alfa
- lutropin alfa
- lutropin alfa
- lutropin alfa
- lutropin alfa
- lutropin alfa
- lutropin alfa
- lutropin alfa for injection
- lutropin alpha
- lutropin alpha
- lutropin beta chain precursor
- luveris
- luveris
- luveris
- luveris
- pergoveris
- recombinant human luteinizing hormone
- r-hlh
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213245 | N/A | Dec 1, 2025 | University of Gothenburg |
| NCT07269327 | Phase 1 | Nov 24, 2025 | Merck KGaA |
| NCT07178405 | N/A | Sep 29, 2025 | University of Gothenburg |
| NCT07121751 | Phase 4 | Sep 1, 2025 | Dunamenti REK Istenhegyi IVF Center, Szeged University |
| NCT06883890 | Phase 2 | Mar 17, 2025 | University of Modena and Reggio Emilia |
| NCT06571214 | Phase 4 | Sep 1, 2024 | Nanjing University |
| NCT06227949 | Phase 3 | Feb 29, 2024 | Merck Serono, University of Toronto |
| NCT05567731 | N/A | Oct 15, 2022 | Tanta University |
| NCT05405686 | Phase 4 | Sep 1, 2022 | Free University of Brussels, Merck KGaA |
| NCT05316935 | Phase 2/Phase 3 (Phase 3) | Jul 13, 2022 | Fudan University |
| NCT04899193 | Phase 1 | May 8, 2021 | Merck KGaA |
| NCT04719000 | Phase 4 | Feb 4, 2021 | Fundación Santiago Dexeus Font, Merck, University Hospital Quirón Dexeus, Barcelona |
| NCT04189133 | Phase 2 | Mar 1, 2020 | University of Modena and Reggio Emilia |
| NCT04178135 | N/A | Nov 25, 2019 | Central South University |
| NCT04037605 | Early Phase 1 (Phase 1) | Jul 24, 2019 | Los Angeles Biomedical Research Institute |
| NCT03882190 | N/A | Apr 1, 2019 | Wenzhou Medical University |
| NCT03741699 | Phase 3 | Feb 18, 2019 | Fundación IVI, Merck, Syntax for Science, University Alicante |
| NCT03400722 | Phase 4 | Dec 1, 2017 | Nova Clinic, Russia |
| NCT03142893 | Phase 1 | May 8, 2017 | Los Angeles Biomedical Research Institute |
| NCT02994550 | Early Phase 1 (Phase 1) | Jan 1, 2017 | Osakidetza |
Showing 20 of 60 trials
Page 1 / 3
Organizations
Research & Development (61)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 13 | 12 | 4 | 1999 |
| Merck Serono | For profit | 12 | 2 | 4 | 1999 |
| Merck | For profit | 6 | 0 | 3 | 2004 |
| Hospitalsenhed Midt | Academic/Hospital | 3 | 2 | 1 | 2003 |
| Central South University | Academic/Hospital | 2 | 1 | 2 | 2009 |
| Free University of Brussels | Academic/Hospital | 2 | 2 | 1 | 2005 |
| Los Angeles Biomedical Research Institute | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Nanjing University | Academic/Hospital | 2 | 1 | 2 | 2009 |
| University of Gothenburg | Academic/Hospital | 2 | 2 | 1 | 2025 |
| University of Modena and Reggio Emilia | Academic/Hospital | 2 | 2 | 1 | 2020 |
| University of Valencia | Academic/Hospital | 2 | 2 | 1 | 2005 |
| Assuta Ashdod Hospital | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Bioroma | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Catholic University of Sacred Heart, Rome | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Centro Riproduzione e Andrologia | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Chongqing Medical University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Dunamenti REK Istenhegyi IVF Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Fundación IVI | Academic/Hospital | 1 | 0 | 1 | 2019 |
61 organizations
Page 1 / 4